Reference number : GC-2017-Q4-01340, amendment number : , agreement type : G, recipient legal name : Navarre, William (University of Toronto), recipient country : CA, recipient province : nan, recipient city : Ontario, recipient postal code : nan, program name english : Engage Grants for universities, program name french : Subventions d'engagement partenarial pour les universités, program purpose english : There is an increasing awareness that our microbiota plays an important role in a variety of pathological_x000D_
disorders including obesity, diabetes, Parkinson's disease, multiple sclerosis, and colorectal cancer._x000D_
Personalized medicine will evolve to include assays for the presence or absence of particular microbes in_x000D_
complex samples (e.g. stool). Most microbes are uncultivable and current genomic sequencing techniques are_x000D_
high resolution but slow and expensive. There will be an increasing need for targeted, inexpensive, and rapid_x000D_
culture-free methods to identify particular microbes from a variety of patient and environmental samples._x000D_
MassArray technology is used to identify genetic polymorphisms for genetic testing. MassArray involves_x000D_
the selective PCR amplification of as many as 40 different loci (multiplex PCR), where specific variants_x000D_
(mutations) are subsequently identified by mass spectrometry (MALDI-TOF). Arctic Diagnostics Inc._x000D_
(ArcticDx, Toronto) has extensive experience in the use of MassArray, performing ~100,000 genetic tests on_x000D_
patients over the past 5 years to identify risk alleles for macular degeneration, cystic fibrosis, and gestational_x000D_
diabetes. Given recent evidence that microbiota play a role in each of these diseases, ArcticDx is motivated to_x000D_
expand the application of their MassArray to identify specific microbial "fingerprints" in patient samples._x000D_
Toward this end Arctic wishes to establish a collaboration with Dr. William Navarre (University of_x000D_
Toronto), a microbiologist who has spent the past three years developing tools to culture and analyze_x000D_
microbiota samples from both humans and mice. We have developed a clear and technically feasible plan to_x000D_
determine if MassArray technology can be employed to simultaneously identify the presence or absence of up_x000D_
to 20 specific microbes from complex (mouse stool) samples. This will involve the development of multiplex_x000D_
primer sets specific to individual microbial species and troubleshooting the PCR, MALDI-TOF, and_x000D_
computational parameters necessary to achieve acceptable levels of specificity and selectivity., program purpose french : There is an increasing awareness that our microbiota plays an important role in a variety of pathological_x000D_
disorders including obesity, diabetes, Parkinson's disease, multiple sclerosis, and colorectal cancer._x000D_
Personalized medicine will evolve to include assays for the presence or absence of particular microbes in_x000D_
complex samples (e.g. stool). Most microbes are uncultivable and current genomic sequencing techniques are_x000D_
high resolution but slow and expensive. There will be an increasing need for targeted, inexpensive, and rapid_x000D_
culture-free methods to identify particular microbes from a variety of patient and environmental samples._x000D_
MassArray technology is used to identify genetic polymorphisms for genetic testing. MassArray involves_x000D_
the selective PCR amplification of as many as 40 different loci (multiplex PCR), where specific variants_x000D_
(mutations) are subsequently identified by mass spectrometry (MALDI-TOF). Arctic Diagnostics Inc._x000D_
(ArcticDx, Toronto) has extensive experience in the use of MassArray, performing ~100,000 genetic tests on_x000D_
patients over the past 5 years to identify risk alleles for macular degeneration, cystic fibrosis, and gestational_x000D_
diabetes. Given recent evidence that microbiota play a role in each of these diseases, ArcticDx is motivated to_x000D_
expand the application of their MassArray to identify specific microbial "fingerprints" in patient samples._x000D_
Toward this end Arctic wishes to establish a collaboration with Dr. William Navarre (University of_x000D_
Toronto), a microbiologist who has spent the past three years developing tools to culture and analyze_x000D_
microbiota samples from both humans and mice. We have developed a clear and technically feasible plan to_x000D_
determine if MassArray technology can be employed to simultaneously identify the presence or absence of up_x000D_
to 20 specific microbes from complex (mouse stool) samples. This will involve the development of multiplex_x000D_
primer sets specific to individual microbial species and troubleshooting the PCR, MALDI-TOF, and_x000D_
computational parameters necessary to achieve acceptable levels of specificity and selectivity., agreement title english : Development of Rapid and High-Throughput Genetic Fingerprinting Assay for the Identification of Specific Intestinal Microbes, agreement title french : Development of Rapid and High-Throughput Genetic Fingerprinting Assay for the Identification of Specific Intestinal Microbes, agreement number : EGP, agreement value : 25000.0, agreement start date : 2018-03-22, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year (2017-2018 to 2018-2019)., additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier (2017-2018 à 2018-2019)., owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada